<b>Edit References</b>	5
------------------------	---

All information in a reference can be edited from Study Inspector or within each module.

## **1. Navigate to the Abstract of interest**

If you are already on the reference of interest, simply go to the Abstract tab.

If you are searching for the record you need to edit, the best way to search is from Inspector.

# 2. Click the Edit button

Abstract Full Text Supplements Related Reports

The button is found at the lower right of the reference information.

Thonsgaard, 2022 **Girculating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.** BACKGROUND C-type natriuretic peptide (CNP) is a cardioprotective peptide with high affinity for the ectoenzyme neutral endopeptidase (neprilysin). We aimed to determine whether angiotensin receptor-neprilysin inhibitor treatment acutely affects circulating concentrations of bioactive CNP and its molecular amino-terminal precursor (NT-proCNP). METHODS We included 9 and 10 healthy young men in 2 randomized crossover trials with <u>sacubitril/valsartan</u> vs control (Trial 1) and <u>sacubitril/valsartan</u> and sitagliptin vs sitagliptin (Trial 2). The participants were randomized to a single dose of <u>sacubitril/valsartan</u> (194/206 mg) or control at the first visit 30 min prior to a standardized meal intake. We obtained blood samples at 12 time points over 5 h and measured plasma concentrations of NT-proCNP in both trials and CNP in Trial 2. RESULTS NT-proCNP concentrations increased 3.5 h after <u>sacubitril/valsartan</u> treatment, and at 4.5 h concentrations were 42% and 65% higher compared with control in Trial 1 and Trial 2, respectively. The total area under the curve (tAUC)15-270 min was 22% higher (P = 0.007) in Trial 1 and 17% higher with treatment (P = 0.017) in Trial 2. Concentrations of bioactive CNP followed a similar temporal pattern with an increase of 93% at 4.5 h and a 31% higher tAUC15-270 min compared with control (P = 0.001) in Trial 2. CONCLUSIONS <u>Sacubitril/valsartan</u> augments circulating concentrations of both bioactive CNP and NT-proCNP in healthy young men. The increase in bioactive CNP is most likely caused by de novo synthesis and secretion rather than diminished breakdown through neprilysin inhibition.ClinicalTrials.gov registration number NCT03717688.

Population/Problem Intervention Outcome	)Your Keywords 🖉 —	
Keywords	Sibliographic fields	✓ Edit

### 3. Add, remove, or modify the information.

In the modal that appears, any Bibliographic Data can be changed by typing in the relevant field.

#### **Changing Author Order**

Author order can be modified using the buttons to the right (red box in the image below).

- Authors can be reordered using the arrows to the side.
- Authors can be removed using the minus button next to the author's name.

PubMed

Last update: 2022/11/20 wiki:autolit:search:editreferences https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:search:editreferences&rev=1668911248 02:27

• Authors can be added below any existing author using the plus button next to the existing author's name.

	)
Drug or Device Mar	
Last Name:	Merge
	Merge
) ( Prickett	$(\checkmark \land) (-+)$
Last Name:	Merge
Hansen	$(\checkmark \land) (-+)$
Last Name:	Merge
Wewer Albrechtsen	$\overline{)} (\overline{)} (\overline{)}$
Last Name:	Merge
Andersen	(
Last Name:	Merge
Terzic	(
Last Name:	Merge
Plomgaard	
Last Name:	Merge
Gustafsson	
Last Name:	Merge
Goetze	
Last Name:	Merge
) ( Mark	
	Last Name: Hansen Last Name: Wewer Albrechtsen Last Name: Andersen Last Name: Terzic Last Name: Plomgaard Last Name: Gustafsson Last Name: Goetze Last Name:

#### 4. Click Save

The save button is found at the bottom of the Edit Metadata window (purple box in the image above).

From: https://wiki.nested-knowledge.com/ - Nested Knowledge

Permanent link: https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:search:editreferences&rev=1668911248

Last update: 2022/11/20 02:27